{"name":"Fate Therapeutics","slug":"fate-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"FT825","genericName":"FT825","slug":"ft825","indication":"Other","status":"phase_1"},{"name":"Single FT1050 treated UCB unit","genericName":"Single FT1050 treated UCB unit","slug":"single-ft1050-treated-ucb-unit","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"FT825","genericName":"FT825","slug":"ft825","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Single FT1050 treated UCB unit","genericName":"Single FT1050 treated UCB unit","slug":"single-ft1050-treated-ucb-unit","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE1IWGt0aHk5LV9Ra2l3Z2FqQXB5am1RODZZaVIydHJvM2ZMX2R6bFJ4R0VGWjAwU25CdkYzY1VocnAwcGpTcnJTNXhYVU9zanB6Sk5pbE9NVk1OMURLeHM3VEdkWGRlcnPSAWxBVV95cUxOV05WRWNUVmU1Zy1QRzNXQlBwQjlUb2xieU91ekx1SmNQcXEwQ2dxVkxtaThLd21uUzFiaE1pWEVZVVJ3dUQ1RjNTelpyb3hyLVlHa3ZyT3Y5c0ZTQUM2MFRaTFNEYkp2X2E0N3c?oc=5","date":"2026-03-05","type":"pipeline","source":"BioInformant","summary":"The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - BioInformant","headline":"The Pipeline for iPSC-Derived Cell Therapeutics in 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxQOW1kMjVXN0NHcEdPdUhjcnhMMWZOWU9oRW1sVy1oSkVLTE9VVjhrVDRwVk45S1FGbDgtN3B3SWxFTHVRejJqZ3lOLThfaTRfVmVEbExWVmZWbm5VT0xPV2ROMy1EZnZvMC1PaGhTcV9SNnd5OUZLcVlnNlVYc1RzOHkzMnRKdXhYQy1ZVTZYRVFmcGEtRlBkYkI1eFV3WjB2b2paWk1zdzhWOUI0M2hHckhoU0tpdHFMYXFERURjb3JQM0lCMllnV3dBT3pUZmk5eXUtMFBJMzNSc1BZWUZDV2VhRkQ2UEYxOHB3NWdjc3Z5VlN3eVBlNzFwTzRqVy1NNnZvZw?oc=5","date":"2026-02-26","type":"earnings","source":"globenewswire.com","summary":"Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates - globenewswire.com","headline":"Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxNRi05aEdIV0VBTU1ieFpobTNCaVpYQ1R6VHloYzVsVXpUQlltTFE4UzRKQ0R5cmgza0RMS0ltUUJLbTR0RnBaY3hDbWcwaGZxb18weWYteUJSMEUzb0ppbTVrX1NvdTJqQy16VGlVS0dncGg0bDRTSmQtNlNSc2ZTU19kcEdSNERJMXhGdGM2Zm80Ym5YanFvQ2d2YWo1VHJVWE1aS0k2Uzc2eUhKSDJkNWtBWVMwZ0RjWXI5QnFvMEh3aEwyS3hDYXB1amNHYVkzc3RNQ3MzTEpuSzZZbXk4VTBSLVBDNE8wc2xjdDhWZUt4YUhsS3RCd2tzTHRqajYwVE5rWTJydUZWZTJ4Y1JUcDFLbXBrMmlZX3dVR3JFSFJibnJNZmc2ekUzWQ?oc=5","date":"2026-02-16","type":"trial","source":"globenewswire.com","summary":"IPSC-derived NK Cells Clinical Trial Pipeline Gains - globenewswire.com","headline":"IPSC-derived NK Cells Clinical Trial Pipeline Gains","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQZklZNXBBSi1YalNSSHVTTU9UaEFqZmtjUS1ybUliaG1RUXp0bEQtX1ZuVEN3c0RMY0ZIUlJGR0lzMldWZWZlUGhQTlVRcEgzTGFaQWw5cTFQTmVEQzF2bFVBY3luMU5fa0FuQjNyR2V0WXFZNjFpQ21DTmh5YmxKZ0RKMW1mNHlJcjdoZXBNUWpDcll1T2d0elpoY2NQZDNkeUVJQVY3cjluYnhHN3MyUkM0REJxUkZlQ2hr?oc=5","date":"2026-02-11","type":"trial","source":"Fierce Biotech","summary":"'The only thing that saves us is data': Allogeneic CAR-T biotechs fight for relevance as industry moves on - Fierce Biotech","headline":"'The only thing that saves us is data': Allogeneic CAR-T biotechs fight for relevance as industry moves on","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-17","type":"pipeline","source":"simplywall.st","summary":"Great week for Fate Therapeutics, Inc. (NASDAQ:FATE) institutional investors after losing 6.3% over the previous year - simplywall.st","headline":"Great week for Fate Therapeutics, Inc. (NASDAQ:FATE) institutional investors after losing 6.3% over the previous year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9EckM1ZG13bndvUTBSODJUR0liQk9NSFktYVZnbjdkS200bjVWWW94N29pM09aU3dtN0dkaFhmLTJTa2ZSS0xCYnZ6VnlNU3lBeU1WNElPcm1NUElGN2taVlA0cmFIVXRwaUZFdXBKdW1kVGJWemRXQVMxUHg?oc=5","date":"2025-12-30","type":"pipeline","source":"Global Growth Insights","summary":"Who Are the Top 19 NK Cell Therapy Companies Globally? - Global Growth Insights","headline":"Who Are the Top 19 NK Cell Therapy Companies Globally?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9iVUFUYkF6aGt3akxZT0hGaW1LLTVITDlQdFFCYUZkc2IwaDJKSHZpQ1d2VmtPWldraV9yWm9idUZab0xqcWZzdXllQ1BIaF9WUGVxcFJMNWhPakFld2QzRVg2dElTbkZjVjdzcEY3QmtFRG96SzhTT25aMkY?oc=5","date":"2025-12-17","type":"pipeline","source":"Fierce Biotech","summary":"Fierce Biotech Layoff Tracker 2025: Voyager jettisons 30 staffers; Mythic and Areteia shutter - Fierce Biotech","headline":"Fierce Biotech Layoff Tracker 2025: Voyager jettisons 30 staffers; Mythic and Areteia shutter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPbFhzRFVlODRweEI5WUpzM2VXamhDTDJ5MFRoc1JUdzdKUGNqZEY1eGNMZWxiYWJYS3ZnYjFfaTdod1hQWHNtVzVrZFF1b2lnUmNXbERORVdFZE5lNjlTRFVnVXNQLWlOb3I4cHpjOGNjcHNrNURaVGZ2aHVCWHZLMmYzMG9PeUFFaUI0SA?oc=5","date":"2025-10-02","type":"pipeline","source":"BioPharma Dive","summary":"Galapagos to decide on fate of cell therapy business ‘within weeks’ - BioPharma Dive","headline":"Galapagos to decide on fate of cell therapy business ‘within weeks’","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNOGZ0azlUZ0Zlam02TnFvZnJuZGtVVzBTUDJ3Z3dObkEwTk1MRGpMYkNHdGVJTUwzWTdFaE11X0VPUXJ2ZkdidE9HVDR3U3ljT0pYYWV6eXpyU3QtNS1UVy02UU54MklrNlA2SURqSEhHVUJZNTA4VDU5clBMekIzSTQwLU1uZGZzSXdSR3E1ampHS0hGOUgzMmVZT0JtMjYzQ3g5TUdKYkl6QQ?oc=5","date":"2025-08-14","type":"pipeline","source":"Pharmaceutical Executive","summary":"Layoffs Continue Across Biotech Industry as More Companies Restructure and Reprioritize - Pharmaceutical Executive","headline":"Layoffs Continue Across Biotech Industry as More Companies Restructure and Reprioritize","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5UYUtjeF9vZUVHMHZTNWdtMlBwM2s1MXpZV3ZUNjhVR3NMNUVFWi1UQjV0Zlo2aVhnWnQ1TjRYSG9oRVlMRGdUaVRCUGtRTjk4a0dZ?oc=5","date":"2025-08-13","type":"pipeline","source":"FirstWord Pharma","summary":"Biotech layoffs: Fate, Generation Bio, ORIC trim teams and pipelines - FirstWord Pharma","headline":"Biotech layoffs: Fate, Generation Bio, ORIC trim teams and pipelines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPRFRBLXk5cGdfRk5ORERPRW9tbnYzLWFpMVY3dkZoYWhQVDYtSGJ5aEpBdzdOYXM5NTlJNzFFX1VteDBCTWQ1THB3WUdIWkZEWHotY2dPTFRya2dyaHFLemkzMUhiQkloWTN3MzdZdU83XzJZdXBqU2ZrYTlDOTJwV1VZSTN0RGRIcFFqakdhdFVPdGZaYi1MUDFMWFkzT1N2MENXUk9wQm5sckNrVFkzdmpn?oc=5","date":"2025-05-08","type":"pipeline","source":"Seeking Alpha","summary":"Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector - Seeking Alpha","headline":"Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE56WUY1dGxGTUdQNnBLU29BdExmNHNzdHpzRmx2QjlHamM3V3VrS19jLVNkOVl6Sk5jMUlFdFo5Y21iREdoYlQ2X0VTUXBkMFhYRVhNeDZJQldwbHUxbklPeXRFYzVaODhfdWNjaXA0Y1JZNXR2NmRjLQ?oc=5","date":"2024-12-02","type":"pipeline","source":"Pharmaceutical Technology","summary":"Fate Therapeutics announces Bob Valamehr as president and CEO - Pharmaceutical Technology","headline":"Fate Therapeutics announces Bob Valamehr as president and CEO","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}